Artificial intelligence (AI) software developer MaxQ AI has signed a distribution agreement with AI software provider EnvoyAI, a subsidiary of advanced visualization (AV) technology firm TeraRecon.
Under the deal, MaxQ AI's Accipio intracranial hemorrhage (ICH) platform will be available on the EnvoyAI Exchange marketplace in the U.S. and European Union. Furthermore, the company's Accipio Ix ICH identification and triaging software will be sold through EnvoyAI and TeraRecon's PACS distribution channels, as well as to TeraRecon's current installed base, according to the companies.
Accipio Ix has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the CE Mark.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
